Changes in Hong Kong stocks | Junshi Biotech (01877) rose more than 3% in early trading, 2 new indications of Tuoyi® and Junstar® were included in the national health insurance catalogue

The Zhitong Finance App learned that Junshi Biotech (01877) rose more than 3% in early trading. As of press release, it had risen 3.23% to HK$24.28, with a turnover of HK$3.177 million.

^{According to the news, Junshi Biotech announced that recently, Shanghai Junshi Biomedical Technology Co., Ltd. (hereinafter referred to as the “Company”) product treprilizumab injection (trade name: Tuoyi ®, product code: JS001) has been successfully included in the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2025)” (hereinafter referred to as the “National Health Insurance Catalogue”) B} JS002 Class scope. The new version of the National Health Insurance Catalogue will be officially implemented on January 1, 2026.

^{As of the disclosure date of this announcement, the company's 4 commercial products Tuoyi ®, adalimizumab injection (trade name: Junmaikang®, product code: UBP1211), remidavir deuterium hydrobromide tablets (trade name: Mindevil®, product code: VV116/JT001), and Junstar ® have all been included in the national medical insurance catalogue. Tuoyi® has all 12 indications approved for marketing in mainland China. It is the only anti-PD-1 monoclonal antibody drug used to treat kidney cancer, triple-negative breast cancer, and melanoma in the catalogue; Junshida® was included for the first time and is the only domestically produced PCSK9 target drug for people who are intolerant to statins in the new catalogue.}